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ABSTRACT
Objective The gross majority of colorectal cancer cases
results from aberrant Wnt/β-catenin signalling through
adenomatous polyposis coli (APC) or CTNNB1
mutations. However, a subset of human colon tumours
harbour, mutually exclusive with APC and CTNNB1
mutations, gene fusions in RSPO2 or RSPO3, leading to
enhanced expression of these R-spondin genes. This
suggested that RSPO activation can substitute for the
most common mutations as an alternative driver for
intestinal cancer. Involvement of RSPO3 in tumour
growth was recently shown in RSPO3-fusion-positive
xenograft models. The current study determines the
extent into which solely a gain in RSPO3 actually
functions as a driver of intestinal cancer in a direct,
causal fashion, and addresses the in vivo activities of
RSPO3 in parallel.
Design We generated a conditional Rspo3 transgenic
mouse model in which the Rspo3 transgene is expressed
upon Cre activity. Cre is provided by cross-breeding with
Lgr5-GFP-CreERT2 mice.
Results Upon in vivo Rspo3 expression, mice rapidly
developed extensive hyperplastic, adenomatous and
adenocarcinomatous lesions throughout the intestine.
RSPO3 induced the expansion of Lgr5+ stem cells,
Paneth cells, non-Paneth cell label-retaining cells and
Lgr4+ cells, thus promoting both intestinal stem cell and
niche compartments. Wnt/β-catenin signalling was
modestly increased upon Rspo3 expression and mutant
Kras synergised with Rspo3 in hyperplastic growth.
Conclusions We provide in vivo evidence that RSPO3
stimulates the crypt stem cell and niche compartments
and drives rapid intestinal tumorigenesis. This establishes
RSPO3 as a potent driver of intestinal cancer and
proposes RSPO3 as a candidate target for therapy in
patients with colorectal cancer harbouring RSPO3
fusions.
INTRODUCTION
Although in the majority of colorectal cancer cases
the Wnt/β-catenin pathway is deregulated through
mutations in adenomatous polyposis coli (APC) or
β-catenin (CTNNB1), two studies reported gene
fusions of the R-spondin family members RSPO2 and
RSPO3 in a subset of human colon tumours, accom-
panied by enhanced expression of these genes.1 2
R-spondins are secreted proteins that potentiate
Wnt/β-catenin signalling following binding of the
leucine-rich repeat-containing G-protein coupled
receptors (LGR), in the intestine represented by
LGR5 and LGR4. Whereas LGR5 predominantly
marks the cycling stem cells at the crypt bottom
that fuel the continuous renewal of the intestinal
epithelium, LGR4 is present throughout the entire
crypt, on cycling stem cells, transient amplifying
cells and Paneth cells.3 4 Paneth cells fulﬁl a crucial
role in the intestinal crypts by providing the stem
cells with a supporting niche.5 In addition to the
cycling stem cells, a pool of more quiescent +4
stem cells has been identiﬁed that coexpress Lgr5
and Paneth cell markers.6–8 These label-retaining
cells (LRCs) serve as Paneth cell precursors and as
‘reserve’ stem cells, able to acquire cycling capaci-
ties upon damage.7 8
RSPO2 and RSPO3 fusions are mutually exclusive
with APC and CTNNB1 mutations in human colon
Signiﬁcance of this study
What is already known on this subject?
▸ Overactivation of Wnt/β-catenin signalling
through APC or CTNNB1 mutation underlies the
majority of colorectal cancer cases.
▸ A subset of human colon tumours harbour
gene fusions of RSPO2 or RSPO3, associated
with enhanced expression of these genes.
▸ R-spondin proteins promote Wnt/β-catenin
signalling.
▸ Inhibition of RSPO3 reduces the growth of
existing RSPO3-fusion-positive tumours in
xenograft models.
What are the new ﬁndings?
▸ Rspo3 expression causes rapid development of
adenoma and adenocarcinoma in the intestine,
establishing RSPO3 as an efﬁcient, causal driver
of intestinal cancer. RSPO3 drives extensive
crypt hyperplasia and expands multiple crypt
components, including Lgr5+ stem cells, Paneth
cells, non-Paneth cell label-retaining cells and
Lgr4+ cells.
▸ The robust RSPO3-induced phenotype is
associated with a modest increase in Wnt/
β-catenin signalling.
How might it impact on clinical practice
in the foreseeable future?
▸ The potency of RSPO3 to stimulate the crypt
stem cells and niche cells, and to actively drive
tumorigenesis, proposes RSPO3 as a useful
candidate target for therapy in patients with
colorectal cancer harbouring RSPO3 fusions.
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tumours, suggesting that a gain in RSPO can substitute for these
most common mutations as an alternative driver of intestinal
tumorigenesis.1 Moreover, all the RSPO-fusion-positive colon
tumours were described to harbour a mutation in either KRAS
or BRAF, mutations that often co-occur in APC mutant settings
as well.1 Involvement of RSPO3 in growth of pre-existing
tumours was recently shown in RSPO3-fusion-positive xenograft
models, where anti-RSPO3 treatment inhibited tumour
growth.9 10 Whether indeed solely a gain in RSPO3 has the
potency to act as a causal driver of intestinal cancer remained to
be determined. Here, we demonstrate that RSPO3 is an onco-
genic driver, rapidly causing intestinal cancer and extensive
crypt hyperplasia, concomitantly stimulating stem cells and sup-
portive niche cells.
RESULTS
Rspo3 expression induces extensive intestinal hyperplasia
and tumorigenesis
To investigate the in vivo consequence of a gain in RSPO3, we
generated a conditional Rspo3 transgenic mouse model. The
used Rspo3 transgene was veriﬁed to encode secreted and
biologically active RSPO3 protein using β-catenin luciferase
reporter assays (see online supplementary ﬁgure S1A). In gener-
ating the mouse model, the Rspo3 coding sequence was inserted
in the inverse orientation, ﬂanked by two pairs of oppositely
oriented, homologous Lox sites and behind the ubiquitous
CAGGS promoter (ﬁgure 1 and see online supplementary
ﬁgure S1B). This design enables conditional Rspo3 expression
upon Cre activity. Cre was provided by crossing our Rspo3invf/+
(Rspo3inv) mice to Lgr5-GFP-CreERT2 (Lgr5) mice11 and activa-
tion of the inducible CreERT2 recombinase was achieved by
tamoxifen injection at the age of 2 months, unless mentioned
otherwise. Single transgenic Lgr5 and Rspo3inv animals served
as controls and were treated identically as double transgenic
Lgr5;Rspo3 mice. Efﬁcient expression of sense-oriented trans-
genic Rspo3 upon tamoxifen injection was conﬁrmed in double
transgenic Lgr5;Rspo3 animals exclusively and throughout the
small and large intestine (see online supplementary ﬁgure S1D).
Correspondingly, we conﬁrmed RSPO3 protein expression,
observed in double transgenic mice only (see online supplemen-
tary ﬁgure S1E).
Transgenic Rspo3 expression caused abdominal enlargement
and often led to rectum prolapses in double transgenic animals
within several weeks, urging their analysis mostly within
2 months following induction. The intestines of Lgr5;Rspo3
mice appeared elongated and distended, and microscopic
analysis revealed mucosal thickening caused by extensive epithe-
lial hyperplasia (ﬁgure 2A, B). This robust phenotype was
observed exclusively though in all double transgenic animals.
Hyperplastic lesions extended upwards from crypts to the
lumen, integrating with pre-existing villi and appearing as mul-
tiple microadenomatous nodules, typically showing dislocated
Paneth cells and high rates of mitosis and local necrotic changes
(ﬁgure 2B, C). These lesions were observed throughout the
entire small intestine, in the caecum and proximal colon (see
online supplementary ﬁgure S2A). In addition, the majority of
animals developed adenomas (ﬁgure 2D), some of which even
progressed to adenocarcinomas as indicated by local invasion
(ﬁgure 2E). On average 2.5 (±2.3) tumours, mostly adenomas,
were detected per Lgr5;Rspo3 mouse, most of which developed
in the jejunum, ileum and caecum (ﬁgure 2F, G). When tamoxi-
fen was injected at 25 days of age, the phenotype and tumour
incidence (average 2.6±2.4, see online supplementary ﬁgure S2B)
were comparable to that of mice injected at 2 months of age.
These data provide evidence that Rspo3 drives rapid intestinal
tumorigenesis and extensive hyperplastic growth.
RSPO3 expands Lgr5+ stem cells and Paneth cells
We examined the occurrence of crypt cells by staining for green
ﬂuorescent protein (GFP) representing Lgr5-GFP-CreERT2
expressing cells and lysozyme indicating Paneth cells. In Lgr5
control mice, we observed GFP expression speciﬁcally in the
crypt bottom stem cells and in a stochastic fashion, as has been
reported (ﬁgure 3A upper panel).11 In the intestines of Lgr5;
Rspo3 animals, we noticed an expansion of the Lgr5-GFP+
stem cell zone in hyperplastic and neoplastic lesions (ﬁgure 3A).
In parallel, we observed a clear increase in the abundance of
Paneth cells in the Rspo3-induced lesions in Lgr5;Rspo3 mice
(ﬁgure 3B). Paneth cells were dislocated, presenting higher
upwards towards the lumen, reaching higher up than the Lgr5+
cells. More speciﬁcally in adenoma, Paneth cells were observed
dispersed throughout the entire tumour, whereas Lgr5-positive
cells were present mainly in the lower parts of these lesions.
Notably, Paneth cells were prominently present at the invading
front of adenocarcinomatous lesions, as were Lgr5+ cells
though less consistent. Even in the proximal large intestine,
RSPO3 induced the appearance of lysozyme-positive Paneth
cells, which are normally absent in the mouse large intestine
(ﬁgure 3C). In accordance with the abnormal growth and crypt
expansion observed in Rspo3 expressing mice, proliferation was
clearly enhanced, as well as the amount of Sox9-positive cells
(ﬁgure 4A, B). Nuclear β-catenin was detected in some Paneth
cells though appeared hardly affected by transgenic Rspo3
expression (ﬁgure 4C), suggesting a relatively moderate gain in
Wnt/β-catenin signalling in our Lgr5;Rspo3 model compared
with Apc mutant mouse models. Indeed, we did detect clear
nuclear β-catenin in tumours of age-matched and background-
matched ApcMin mice (see online supplementary ﬁgure S3A).
Taken together, RSPO3 imposes hyperplastic, adenomatous and
adenocarcinomatous growth in the mouse intestine, accompan-
ied by expansion of the crypt compartment, including Lgr5+
stem cells, Paneth cells and proliferative progenitor cells.
RSPO3 causes expansion of additional crypt cell types
In the setting of Apc deletion in Lgr5 cells, Lgr5+ stem cells
have been reported as the cells of origin in the developing
adenoma.12 13 We performed lineage tracing experiments to
examine a possible Lgr5+ stem cell derivation of the
Rspo3-induced lesions. Lgr5;Rspo3 mice were cross-bred to
mTmG Cre reporter mice, enabling detection of an intense GFP
signal in the progeny upon Cre-mediated switching, well distin-
guishable from the weaker GFP staining derived from the
Lgr5-GFP-CreERT2 cassette. In Lgr5;mTmG mice without trans-
genic Rspo3, ribbons of GFPhi staining presented from the
crypts upwards into the villi (ﬁgure 5A). However, upon Rspo3
expression the overall occurrence of GFPhi cells seemed
reduced, appearing less frequent and only in small foci, leaving
the vast majority of the Rspo3-induced hyperplasias and
tumours untraced (ﬁgure 5A). A similar reduction in lineage
tracing was observed upon Rspo3 expression using Rosa26-LacZ
mice as a Cre reporter (ﬁgure 5B). Although stochastic expres-
sion and suboptimal efﬁciency of Cre could cause under-
representation of Lgr5-derived lineage tracing, this holds true
both for mice expressing as well as lacking transgenic Rspo3,
and thus cannot explain the relative reduction in
Lgr5-Cre-driven lineage tracing in Rspo3 expressing mice. This
indicates that Lgr5+ cells are not the sole cells of origin and
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alternative cell types must be involved in the development of
the Rspo3-driven lesions.
Given that RSPO3 is a secreted protein, most likely it will act
not only in an autocrine but also in a paracrine fashion on adja-
cent cells expressing the LGR5 and LGR4 receptor. Lgr4 has
been reported to be expressed throughout the entire crypt com-
partment, present on crypt base columnar cells, Paneth cells and
transient amplifying cells.4 Lgr4 in situ hybridisation revealed
that Lgr4+ cells presented abundantly throughout the entire
Rspo3-induced lesions, demonstrating the efﬁcient expansion of
these cells upon Rspo3 expression (ﬁgure 5C). This abundance
of Lgr4+ cells is in contrast to the more sparsely present Lgr5+
cells, which were restricted to the lesion bases (ﬁgures 3B
and 5C). Importantly, a comparable distribution pattern of
LGR4+ and LGR5+ cells was observed in xenografts of
RSPO3-fusion-positive human colon tumours. In these patient-
derived tumours, LGR5 expression was limited and focal,
whereas LGR4 was expressed abundantly throughout the entire
tumours, conﬁrming the expansion of LGR4+ cells in the
human situation (ﬁgure 5D).
In addition to the cycling stem cells, more quiescent stem
cells were recently identiﬁed that coexpress Lgr5 and Paneth cell
markers. In contrast to the crypt bottom stem cells, these cells
are label-retaining, a feature that also holds true for Paneth cells.
Moreover, these quiescent cells which are located at the +4 pos-
ition serve as Paneth cell precursors and as ‘reserve’ stem cells,
acquiring cycling stem cell capacities under speciﬁc circum-
stances.7 8 To investigate the inﬂuence of RSPO3 on these quies-
cent cells, we performed repetitive bromodeoxyuridine (BrDU)
injections, and allowed label retention for 1 week or 2 weeks,
which was the maximum we could achieve given the Rspo3-
induced morbidity. Subsequently, double staining was performed
for BrDU and lysozyme, allowing discrimination between
non-Paneth and Paneth cell LRCs. Transgenic Rspo3 expression
clearly enhanced the presence of total LRCs, 1 week and
2 weeks following BrDU injections (see online supplementary
ﬁgure S3B and ﬁgure 5E, F respectively). Moreover, among
these LRCs, lysozyme-negative LRCs were especially enhanced
upon Rspo3 expression, indicating a relative increase in
non-Paneth cell LRCs, or, the presumptive Paneth cell precur-
sors that may acquire stem cell activities.
Together these data indicate that Rspo3 induces lesions that
are only partially derived from Lgr5+ cells, though in parallel
causes an abundant expansion of Lgr4+ cells, label-retaining
Paneth cells and their presumptive quiescent precursors.
RSPO3 imposes a crypt-associated gene expression proﬁle
RNAseq analysis was performed on jejunum tissue of Lgr5 and
Rspo3inv single transgenic control mice and Lgr5;Rspo3 double
transgenic animals (n=8 per genotype). Unsupervised clustering
on gene expression proﬁles showed tight clustering of Lgr5;
Rspo3 tissues (see online supplementary ﬁgure S4). Lgr5 and
Rspo3inv single transgenic controls clustered together, indicating
their similarity and justifying to pool them as controls. We
found 587 differentially expressed genes of which 255 were
increased and 332 decreased (ﬁgure 6A, ﬁltered p<0.05 and
fold change >1.5). Gene ontology analysis revealed that most
signiﬁcantly enriched molecular and cellular functions upon
Rspo3 expression were related to cellular growth, proliferation,
movement and signalling (ﬁgure 6B). Wnt/β-catenin signalling
appeared as the second most signiﬁcantly upregulated signalling
pathway, while an increased expression of phosholipase genes
Pla2g5, Pla2g2a, Pla2g2f, Pla2g4c and Pla2g12a underlied high
ranking of the majority of the other pathways, except for the
axonal guidance pathway (ﬁgure 6B and see online
supplementary ﬁgure S5A). Taking a closer look at individual
genes involved in cellular proliferation, growth and Wnt/
β-catenin signalling in the intestine, we found a broad panel of
genes among the upregulated genes. In addition to 12 upregu-
lated Wnt signalling related genes, we observed increased tran-
scripts of crypt stem cell markers Ascl2, Hopx, Cdca7, Tnfrsf19
and Msi1 and of Paneth cell associated genes Lyz1 and Pla2g2a
(ﬁgure 6C). Also, enhanced Lgr4 expression was observed, cor-
responding to the above described expansion of Lgr4+ cells.
Conversely, differentiation markers of non-crypt cell lineages
were downregulated, among which Sis and Muc2, and most
signiﬁcantly downregulated functions involve metabolism
and associated signalling pathways (see online supplementary
ﬁgure S5B–D). These expression data match our ﬁndings of
abnormal cellular growth and crypt hyperplasia, including
expansion of Lgr4+, Paneth and stem cells and also indicate
signiﬁcantly increased Wnt/β-catenin signalling.
To assess whether the increased mRNA levels of
crypt-associated genes solely reﬂects the expansion of crypt cells
or also concerns differential gene expression at the cellular
level, Lgr5-GFP stem cells and Paneth cells were sorted by ﬂow
Figure 1 Simpliﬁed schematic representation of the Rspo3 inv mouse model. The Rspo3 coding sequence is inserted in the inverse orientation
between two pairs of oppositely oriented Lox sites and behind the CAGGS promoter. Cre activity causes inversion of the Rspo3 transgene into the
sense orientation using either one of the homologous LoxP or Lox511 pairs, leading to the middle two transgenic Rspo3 products. Subsequent
excision of the remaining sequences in between the homologous Lox sites that are now in the same direction provides a product with sense
oriented, irreversible Rspo3 expression. Both intermediate and locked Rspo3 recombination products encode Rspo3 sense mRNA.
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cytometry6 from Lgr5 single transgenic control and Lgr5;Rspo3
double transgenic mice. Expression of Lgr5 and lysozyme being
restricted to the sorted Lgr5-GFP and Paneth cell populations,
respectively, conﬁrmed correct identity of the sorted cells. Gene
expression analysis using quantitative PCR revealed enhanced
expression of stem cell markers Lgr5, Ascl2 and Prom1 in sorted
Lgr5+ stem cells upon transgenic Rspo3 expression, and trans-
genic Paneth cells expressed increased levels of lysozyme.
Interestingly, Wnt target genes Axin2, Cd44, Lef1 and Sox9
were upregulated not only in Lgr5+ stem cells, but also in Paneth
cells, as was the case for Lgr4 as well. Together these data indi-
cate that RSPO3 promotes the expression of Wnt target genes,
stem cell and Paneth cell genes by expanding the population of
concerning cells, and additionally by stimulating the expression
of these stemness-associated genes at the cellular level.
RSPO3 alters organoid morphology and enables
RSPO1-independent growth
Investigating the growth of intestinal organoids from our Lgr5;
Rspo3 transgenic mice, we noticed that shortly after seeding,
the vast majority of Lgr5;Rspo3 transgenic organoids typically
presented as large cysts, or spheres, as has been described for
other Wnt activating culture conditions5 and clearly distinct
from the appearance of control organoids (ﬁgure 7A, B). Lgr5;
Figure 2 Rspo3 induces extensive intestinal hyperplasia and tumorigenesis. H&E stainings of small intestine of (A) Rspo3inv control and (B-E) Lgr5;
Rspo3 mice, including representative examples of (C) hyperplastic, (D) adenomatous and (E) adenocarcinomatous growth, (C–E) lower panels
showing an enlargement of the boxed regions. (F) Tumour occurrence in Lgr5;Rspo3 animals (n=16) as illustrated by (F) the amount of tumours per
mouse, lines indicating the median, and (G) tumour distribution (percentage of tumours detected per region).
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Rspo3 spheres did not maintain this cystic phenotype over time
but rather showed crypt budding and differentiation after
several days. The crypt regions developing in Lgr5;Rspo3 orga-
noids showed aberrant morphology, with the lumen appearing
open and being relatively large (ﬁgure 7A, B and see online
supplementary ﬁgure S6). Furthermore, whereas control orga-
noids rapidly died following depletion of exogenous RSPO1
from the medium, Lgr5;Rspo3 organoids survived and main-
tained their typical morphological phenotype as observed in the
presence of RSPO1 (ﬁgure 7C), indicating the functional
replacement of exogenous RSPO1 by the transgenic RSPO3.
Robust proliferation capacity of the Lgr5;Rspo3 organoids in
the absence of exogenous RSPO1 was conﬁrmed by Ki67 stain-
ing (ﬁgure 7D).
Mutant Kras enhances RSPO3-induced hyperplastic, though
not neoplastic growth
All human colon tumours with RSPO2 or RSPO3 fusion tran-
scripts harboured a mutation in either KRAS or BRAF.1 To inves-
tigate the relevance of mutant Kras in the setting of enhanced
Figure 3 Rspo3 induces expansion of Lgr5 stem cells and Paneth cells. Immunohistochemical staining of (A) GFP and (B) lysozyme in
representative hyperplastic and neoplastic lesions in the small intestine. (C) Lysozyme staining showing Paneth cell metaplasia in hyperplastic
proximal colon (middle panel) and in adenoma at the caecum-colon transition (lower panel).
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RSPO3, we cross-bred our Lgr5;Rspo3 mice with KrasG12V
mice. F1 hybrid progeny was injected with tamoxifen at 25 days
of age, activating Cre and enabling expression of Rspo3 and
of the mutant Kras allele. Triple transgenic mice expressing
both Rspo3 and mutant Kras (Lgr5;Rspo3;Kras genotype)
appeared more morbid than corresponding Lgr5;Rspo3 con-
trols, although survival did not differ signiﬁcantly between
Lgr5;Rspo3;Kras and Lgr5;Rspo3 cohorts (see online supple-
mentary ﬁgure S7). Lgr5;Kras mice displayed no signs of mor-
bidity and accordingly, microscopic analysis of the intestines
revealed no phenotypical alterations (ﬁgure 8A). However,
mutant Kras activation in combination with transgenic Rspo3
expression revealed an increase in the severity of the hyperplas-
tic phenotype (ﬁgure 8A), indicating that mutant Kras and
RSPO3 synergistically stimulate hyperplastic growth. In contrast,
tumour numbers were not signiﬁcantly different between the
Lgr5;Rspo3 and Lgr5;Rspo3;Kras cohorts (ﬁgure 8B).
Restricted to the Lgr5;Rspo3;Kras cohort, three cases of adeno-
matosis were observed, in which animals displayed multiple
adenomatous lesions throughout the small intestine, merging
into one another and hampering exact quantiﬁcation. Given the
reported synergy between mutant Kras and mutant Apc on Wnt/
β-catenin signalling,14 we performed immunohistochemical
β-catenin stainings on the intestines of mice expressing trans-
genic Rspo3 with and without mutant Kras (ﬁgure 8C). Nuclear
translocation of β-catenin was hardly observed both in Lgr5;
Rspo3 and Lgr5;Rspo3;Kras intestines. Accordingly, qPCR ana-
lyses showed that RSPO3 increased the expression of Axin2,
Cd44, Sox9 and Rnf43, but coexpression of the mutant Kras
allele from the Lgr5-GFP-CreERT2 cells did not raise the expres-
sion levels any further (ﬁgure 8D). Together these data indicate
that in this mouse model, when expressed in Lgr5+ cells,
mutant Kras synergises with RSPO3 in hyperplastic growth, but
not in promoting Wnt signalling or tumorigenesis.
DISCUSSION
Recognising the prominent role of APC and CTNNB1 mutations
in human colorectal cancer, many mouse studies have invest-
igated the effects of activating the associated Wnt/β-catenin
signalling pathway, showing proliferative and tumorigenic
Figure 4 Rspo3-induced lesions are highly proliferative. Immunohistochemical staining of (A) Ki67, (B) Sox9 and (C) β-catenin in representative
Rspo3-induced lesions. Inserts show predominant membranous β-catenin expression besides mild nuclear detection in Paneth cells.
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phenotypes.12 15–21 Gene fusions leading to enhanced RSPO3
expression have been proposed as a possible alternative to these
most common APC or CTNNB1 mutation routes in driving
intestinal cancer.1 We show that transgenic Rspo3 expression
induces a proliferative phenotype resembling that of other Wnt
activating mouse models. Moreover, we provide in vivo evi-
dence that RSPO3 stimulates stem cell and niche compartments
and drives rapid intestinal tumorigenesis. In line with reported
Wnt/β-catenin promoting activities of R-spondin, transgenic
Rspo3 expression potentiated the Wnt signalling pathway, as
was apparent from multiple gene expression analyses and cystic
organoid morphology. We demonstrated that RSPO3 enhanced
Wnt/β-catenin signalling both in Lgr5+ stem cells and Paneth
cells. Despite this, we hardly observed nuclear translocation of
β-catenin in RSPO3-induced lesions, indicating that the gain in
Wnt signalling is relatively low, especially compared with Apc
mutant mouse models. In this regard, it might be interesting to
investigate the involvement of alternative signalling factors, and
the collective increase of ﬁve phospholipase genes propose these
as interesting candidates. Among those, Pla2g2a has recently
been described as an important regulatory stem cell niche
factor.22
Thus, while RSPO3 raises Wnt/β-catenin signalling to a rela-
tively modest level, it drives tumorigenesis efﬁciently.
Figure 5 Rspo3 expands additional crypt cell types. (A) GFP immunostaining in the small intestine of Lgr5;mTmG mice with or without transgenic
Rspo3. GFPhigh cells indicate mTmG reporter activity, distinguishable from GFPmid cells derived from the Lgr5-GFP-CreERT2 cassette. (B) X-gal staining
of Lgr5;R26-LacZ mice with or without transgenic Rspo3. In situ hybridisation showing Lgr4 and Lgr5 mRNA expression (C) in an Rspo3-induced
adenoma of an Lgr5;Rspo3 mouse and (D) in a xenograft of a human RSPO3-fusion-positive colon tumour. (E) Representative example of
bromodeoxyuridine (BrDU)-lysozyme double immunostaining in Lgr5 single and Lgr5;Rspo3 double transgenic jejunum, 2 weeks after repetitive BrDU
injections. Arrows indicate lysozyme-positive label-retaining cells (LRCs) (black) and lysozyme-negative LRCs (grey). (F) Quantiﬁcation of
BrDU-retaining cells in the jejunum, being either lysozyme-negative or lysozyme-positive (2 weeks after BrDU), showing averages and SDs over three
independent experiments. *p<0.05, **p<0.01, Student’s t-test.
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Importantly, our data also demonstrate that RSPO3 causes an
expansion of Lgr5+ stem cells, Paneth cells, Lgr4+ cells and
LRCs. The capacity to stimulate stem cells and niche cells by
promoting their Wnt signalling and causing their expansion
likely provides RSPO3 with tumorigenic potential. After all, per-
sistent overstimulation of stem cells and their niche cells pro-
vides a solid basis for abnormal, uncontrolled tissue growth.
This is supported by the recent ﬁnding that anti-RSPO3 treat-
ment of existing RSPO3-fusion-positive tumour xenografts inhi-
bits tumour growth and reduces stem cell marker expression.9 10
We demonstrate that stimulation of stemness by RSPO3 thus
goes beyond stimulating the Lgr5+ stem cells themselves and
includes stimulation of Lgr4+ cells, Paneth cells and their pre-
sumptive precursors. Besides providing Lgr5+ stem cells with a
stemness-supporting niche, it is of interest to determine whether
these alternative, expanded cell types contribute to
RSPO3-driven tumorigenesis as a cell of origin. In this regard,
very limited lineage tracing was observed from Lgr5+ cells in
RSPO3-induced lesions, indicating that the lesions derive from
alternative cell types. Supportively, quiescent Paneth cell precur-
sors have been described to acquire cycling stem cell properties
upon tissue damage, serving as a reserve stem cell pool, and
Figure 6 Rspo3 induces a crypt-associated gene expression proﬁle. (A) Heat map of normalised per-sample expression values (2log and n=8 per
genotype), including differentially expressed genes upon transgenic Rspo3 expression (ﬁltered p<0.05 and fold change >1.5). (B) Gene ontology
analysis showing most signiﬁcantly enhanced molecular and cellular functions (upper panel) and signalling pathways (lower panel) upon Rspo3
expression. Grey points indicate the gene ratio per signalling pathway. (C) Wnt pathway and crypt-associated genes enriched upon Rspo3
expression. (D) Relative RNA expression levels in sorted Lgr5-GFP and Paneth cells of either Lgr5 control or Lgr5;Rspo3 transgenic mice as
determined by qPCR. Bars indicate the averages with SDs from three mice per genotype sorted during independent experiments. *p<0.05,
**p<0.01, ***p<0.001, Student’s t-test.
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more differentiated intestinal cell types have been shown to act
as tumour initiating cells under speciﬁc circumstances.8 19 23
Taken together, we demonstrate that RSPO3 stimulates Lgr5+
stem cells, Lgr4+ cells, Paneth cells and their presumptive quies-
cent precursors by causing their expansion as well as promoting
the expression of related genes, including Wnt/β-catenin signal-
ling genes. Considering that R-spondins are secreted proteins,
this implies that RSPO3 may potentially inﬂuence a broad
spectrum of stem cell and niche cell types in patients with colo-
rectal cancer harbouring RSPO3 fusions. Unfortunately, not
much knowledge exists to date about the occurrence and func-
tioning of alternative stem cells, Paneth cells and their precur-
sors in the human colon, besides that part of human colon
tumours harbour Paneth cells, and their presence in adenoma is
associated with an increased risk for developing additional
colonic adenomas.16 24 25 We provide in vivo evidence that
RSPO3 stimulates the intestinal stem cell and niche compart-
ments and drives rapid tumorigenesis, proposing RSPO3 as a
promising candidate therapy target for patients with colorectal
cancer carrying RSPO3 fusions.
MATERIALS AND METHODS
Generation of Rspo3inv transgenic mouse model
A detailed description of the generation of the Rspo3 cassette
that allows conditional expression of Rspo3 after Cre activation,
and the generation of the FVB.129P2-Gt(Rosa)26Sor6
(CAG-Rspo3)Nki/A (MGI:5697338, abbreviated to Rspo3inv) trans-
genic founder strain is provided in the online supplementary
information. Shortly, the Rspo3 coding sequence was inserted in
antisense orientation between two sets of non-homologous Lox
sites in a head to head orientation, 30 to the CAGGS promoter
in a Rosa26 gene targeting cassette.26 The obtained Rspo3inv
construct (ﬁgure 1 and see online supplementary ﬁgure S1A)
was introduced into strain 129 derived IB10 E14ES cells by
electroporation and selected embryonic stem (ES) cells were
injected into 129/Ola blastocysts. Founder strains were back-
crossed for ﬁve times to 129/Ola, followed by more than nine
generations back-crossing to FVB.
Mouse strains and treatments
All mouse strains were maintained heterozygous. The Rspo3inv
mice were provided with inducible Cre by cross-breeding with
Lgr5-GFP-CreERT2 transgenic mice11 on FVB background. Cre
was activated by intraperitoneal tamoxifen injection (200 mL
10 mg/mL in corn oil) of single and double transgenic progeny
at the age of 2 months, followed by analysis 1–2 months later,
unless mentioned otherwise. BrDU was administered by intra-
peritoneally injecting 100 mL (10 mg/mL in phosphate-buffered
saline (PBS)), six times on two consecutive days, and 2 weeks
after tamoxifen. Double transgenic Lgr5-GFP-CreERT2;Rspo3inv
mice were cross-bred to mTmG mice (back-crossed to FVB),27
Rosa26-LacZ mice,28 and KrasLSL G12Vgeo mice.29 Progeny was
injected with tamoxifen at day 25, followed by analysis within
1–2 months.
Histology and immunohistochemistry
Intestines were formalin-ﬁxed and parafﬁn-embedded (FFPE), fol-
lowed by H&E staining according to routine protocols. Cultured
organoids were ﬁxed in 4% PFA and embedded in low-melting
agarose prior to parafﬁn embedding. Immunohistochemistry was
performed on consecutive sections using antigen retrievals, anti-
bodies and visualisation as indicated in online supplementary table
SI. For quantiﬁcation of BrDU/lysozyme-positive cells, Aperio
Figure 7 RSPO3 alters organoid morphology and allows RSPO1-independent growth. (A) Organoids grown from control and Lgr5;Rspo3 transgenic
mice, 2 (upper) and 5 (lower) days after seeding, showing the increase in spheroid growth, aberrant crypt formation and open lumen upon Rspo3
expression. (B) Percentage of spheres of total organoids in culture, bars indicate the averages with SDs from minimally three experiments. *p<0.05,
**p<0.01, Student’s t-test. (C) Organoids from control mice disintegrate following the depletion of exogenous RSPO1, whereas Lgr5;Rspo3
organoids survive and show similar phenotype as with exogenous RSPO1. (D) Ki67 staining visualising proliferation absence and presence in control
versus Lgr5;Rspo3 organoids, respectively, in the absence of exogenous RSPO1.
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ImageScope software was used to precisely discriminate single or
double staining for each cell. Twenty-ﬁve GFP-positive jejunum
crypts were counted per mouse, followed by averaging the three
experiments. X-gal staining was performed as described in the
online supplementary information.
RNA in situ hybridisation
RNA in situ hybridisation was performed using RNAscope 2.0
high deﬁnition (HD) Brown for FFPE (Advanced Cell
Diagnostics (ACD)) and following manufacturer’s instructions
with minor adjustments. Pretreatment (1) 10 min RT, pretreat-
ment (2) boil 15 min and pretreatment (3) 10 min in 40°C
hybridisation oven. Probes Mm Lgr4 318321, Mm Lgr5
312171, Hs LGR4 460551 and Hs LGR5 311021 (ACD) were
hybridised 2 hours at 40°C. Sections of xenograft tumours
derived from RSPO3-fusion-positive human colon tumours were
obtained from Crown BioScience.
RNA isolation, cDNA synthesis and expression analysis
of whole tissue
For the purpose of RNA sequencing analysis, RNA was isolated
from jejunum tissues using TRIzol reagent (Ambion Life
Technologies) followed by puriﬁcation using the MinElute
Cleanup Kit (Qiagen). Illumina TruSeq mRNA libraries were
generated using the TruSeq RNA Library Preparation Kit v2
(Illumina) and samples were sequenced 51 bp single-end using
the Illumina Hiseq2000 platforms (Illumina). Everything was
performed according to routine manufacturer’s protocols.
Figure 8 Mutant Kras and Rspo3 synergise in hyperplastic though not neoplastic growth. (A) H&E stainings of small intestine of Lgr5;Kras, Lgr5;
Rspo3 and Lgr5;Rspo3;Kras mice, showing augmentation of the hyperplastic phenotype in triple transgenic mice. The right-most panel shows a
representative example of adenomatosis as observed in Lgr5;Rspo3;Kras mice exclusively. (B) Number of adenoma (left panel) and adenocarcinoma
(right panel) observed in Lgr5;Rspo3 and Lgr5;Rspo3;Kras mice, lines indicating the median. Open triangles represent cases of adenomatosis, where
tumour numbers are an estimation of ≥20. (C) β-catenin immunostaining on representative neoplastic lesions in small intestine of Lgr5;Rspo3 and
Lgr5;Rspo3;Kras mice. Inserts show that nuclear β-catenin detection is not affected by mutant Kras. (D) Relative expression of Wnt target genes in
the jejunum (n=8 per genotype). **p<0.01, ***p<0.001, Student’s t-test.
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Limma’s Voom was used for normalisation and expression data
were analysed using Ingenuity Pathway Analysis.
For RT-PCR and qPCR purposes, RNA was isolated from
jejunum tissues using TissueLyser LT (Qiagen) and RNeasy Plus
Mini Kit (Qiagen), followed by cDNA generation using Maxima
First Strand cDNA Synthesis Kit (Fisher Scientiﬁc). RT-PCR was
performed using MyTaq Red DNA Polymerase and qPCR using
SensiFAST SYBR Hi-ROX Kit (both GCBiotech). Primers are
shown in online supplementary table SII. Expression levels were
normalised using Actb.
Crypt isolation, culture and cell preparation for ﬂow
cytometric sorting
Small intestinal crypts were isolated and cultured as described,6 30
using mice that received Tamoxifen at the age of 25 days.
Cultured organoids were dissociated with narrowed Pasteurs’
pipettes, seeded into Matrigel (Corning) and maintained for
indicated durations, without or with exogenous RSPO1. RSPO1
was supplemented as 10% conditioned medium, derived from
HEK293Tcells transfected with an Rspo1 expression vector.31
For ﬂow cytometric sorting, isolated crypts were incubated
with TrypLE (Life Technologies) and 2000 U/mL Dnase (Sigma)
10 min, 37°C. Dissociated cells were passed through a 40 μm
strainer and stained 30 min at 4°C with BV421-conjugated-
TER119, BV421-conjugated-CD31, BV421-conjugated-CD45
and APC-conjugated CD24 (all BioLegend). Sorting was per-
formed using FACS AriaIII (BD Bioscience) as described previ-
ously.6 In short, single viable epithelial cells (DAPI− and
lineage−) were selected based on CD24, GFP and side scatter
(SSC). Paneth cells (CD24hiSSChi) and Lgr5-GFPhi stem cells
were sorted in three independent runs.
Expression analysis of sorted cells
RNA was isolated following the Trizol reagent protocol
(Invitrogen), adding 1 mL Glyco-blue (15 mg/mL Ambion). RNA
was converted into cDNA using the high capacity RNA-to-cDNA
kit (Applied Biosystems) and employed in a preampliﬁcation step
using the TaqmanPreAmp Master Mix (Applied Biosystems).
Quantitative PCR was performed using TaqMan probes and
assays (Applied Biosystems). Everything was performed according
to manufacturer’s instructions. Expression levels were corrected
for Actb expression.
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